The number of people with type 2 diabetes worldwide has been estimated to increase from 405.6 million in 2018 to 510·8 million by 2030, according to study by a Stanford University-led research team released on November 20.
The study predicts that African, Asian, and Oceania regions will not get the proper amount of insulin in 2030 if the access remains at current levels.
The untreated person affected by diabetes were affected by the deterioration of heart, kidney, eyes, nerves, blood vessels, stroke, and the major complication is that these high sugar level patients can not undergo surgery because the healing of a surgical wound is slow and complicated. Study Says The Ketogenic Diet Could Increase The Risk For Type 2 Diabetes. According to the calculation of Sanjay Basu from Stanford University in California, the number of people who will need insulin to treat type 2 diabetes will climb by 20 percent in the next decade.
As global rates of type 2 diabetes soar and people with type 2 diabetes live longer, a comprehensive picture of global insulin need is required because insulin treatment is costly, and the worldwide insulin market is presently dominated by only three major manufacturers, they said.
Global insulin supply is dominated by three companies - Novo Nordisk, Sanofi and Eli Lilly - which have various programs to try to improve access to their products.
India had 69.2 million people living with diabetes in 2015 says a report of the World Health Organization
The Guardian quoted Dr. Sanjay Basu from Stanford University in the USA, who led the research, as saying the current levels of insulin access are inadequate especially in Africa and Asia, requiring more efforts to overcome this shortage. Past research has found that insulin cost nearly tripled between 2002 and 2013, underscoring the affordability issue.
"These estimates suggest that current levels of insulin access are highly inadequate compared to projected need, particularly in Africa and Asia, and more efforts should be devoted to overcoming this looming health challenge", said lead author Dr Sanjay Basu. The creators caution that procedures to make insulin all the more broadly accessible and reasonable will be hard to guarantee that request is met.
Executive director of Health Action International (HAI), which funded the study, said: "Governments should use this information to plan for growing need".
Diabetes is a progressive disease and the body may require insulin injections to compensate for declining insulin production by the pancreas.